Home

Brainstorm Cell Therapeutics Inc. - Common Stock (BCLI)

1.8200
-0.0900 (-4.71%)

Brainstorm Cell Therapeutics is a biotechnology company focused on developing innovative therapies aimed at treating neurodegenerative diseases and neurological conditions through the harnessing of stem cell technology

The company is particularly known for its research and development of treatments using its proprietary approach to generating cells that can potentially repair or regenerate damaged tissues in the central nervous system. By leveraging its expertise in cellular therapy, Brainstorm Cell aims to provide new hope for patients suffering from debilitating disorders. Through ongoing clinical trials and research initiatives, the company is committed to advancing its scientific discoveries into effective treatment options.

SummaryNewsPress ReleasesChartHistoricalFAQ
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 16, 2024
BCLI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 2, 2024
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm – BCLI
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 1, 2024
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQBCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm.
By The Rosen Law Firm, P.A. · Via Business Wire · December 31, 2023
BRAINSTORM CELL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQBCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire, P.C. · Via Business Wire · December 29, 2023
BCLI FINAL DEADLINE ALERT: ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Initiated by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 29, 2023
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brainstorm Cell, SolarEdge, and Barclays and Encourages Investors to Contact the Firm
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Brainstorm Cell Therapeutics Inc. (NASDAQBCLI), SolarEdge Technologies, Inc. NASDAQ: SEDGNASDAQSEDG)(NYSE: BCSNYSEBCS. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · December 28, 2023
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced by the Firm – BCLI
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 28, 2023
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQBCLI) securities between August 15, 2022 and September 27, 2023, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · December 28, 2023
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 27, 2023
BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 27, 2023
ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 26, 2023
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 25, 2023
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 24, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQBCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 24, 2023
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 24, 2023
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 23, 2023
ROSEN, A LONGSTANDING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 22, 2023
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQBCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 20, 2023
ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 19, 2023
BRAINSTORM ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 19, 2023
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 17, 2023
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 15, 2023
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQBCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 15, 2023
BRAINSTORM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
By Faruqi & Faruqi LLP · Via GlobeNewswire · December 15, 2023
ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · December 11, 2023